16.80 USD
▼-0.42-2.44%
盘后 16.65 0.00%
2026-09-16
市值
$89.48M
市盈率
2.11
EPS
7.99
股息率
—
52 周区间
3.67 – 17.57
成交量
8.06K
Beta
-0.85
目标价
—
52W 低 3.6752W 高 17.57
价格走势
公司简介
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to ...